Volatile organic compounds in head and neck squamous cell carcinoma—An in vitro pilot study. (24th February 2020)

• Record Type: Journal Article
• Authors: Kulas, Philipp; Seidel, Martin; Bozzato, Alessandro; Schick, Bernhard; Sessler, Daniel I.; Kreuer, Sascha; Hüppe, Tobias
• Is Part Of: Biomedical chromatography. Volume 34:Number 5(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-24
• Subjects: head and neck squamous cell carcinoma -- headspace measurement -- ion mobility spectrometry -- volatile organic compound; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.4811
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Owing to the lack of specific symptoms, diagnosis of head and neck squamous cell carcinoma (HNSCC) may be delayed. We evaluated volatile organic compounds in tumor samples from patients suffering from HNSCC and tested the hypothesis that there is a characteristic altered composition in the headspace of HNSCC compared with control samples from the same patient with normal squamous epithelium. These results provide the basis for future noninvasive breath analysis in HNSCC. Headspace air of suspected tumor and contralateral control samples in 20 patients were analyzed using ion‐mobility spectrometry. Squamous cell carcinoma was diagnosed in 16 patients. In total, we observed 93 different signals in headspace measurements. Squamous cell carcinomas revealed significantly higher levels of volatile cyclohexanol (0.54 ppbv, 25th to 75th percentiles 0.35–0.86) compared with healthy squamous epithelium (0.24 ppbv, 25th to 75th percentiles 0.12–0.3; p < 0.001). In conclusion, head and neck squamous cell carcinoma emitted significantly higher levels of volatile cyclohexanol in headspace compared with normal squamous epithelium. These findings form the basis for future breath analysis for diagnosis, therapy control and the follow‐up of HNSSC to improve therapy and aftercare.